Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

CNS 13Sarcoma 4Lymphoid 3Genitourinary 3Gynecologic 2Gastrointestinal 2Thoracic 1Other solid neoplasm 1Head & Neck 1Classical hematology 1

Conditions

Thrombocytopenia 1Lymphoma 1Intraocular Lymphoma 1Drug-Related Side Effects and Adverse Reactions 1Central Nervous System Neoplasms 1

Interventions

sodium thiosulfate 1pegfilgrastim 1etoposide phosphate 1Temozolomide 1Rituximab 1Radiotherapy 1Granulocyte Colony-Stimulating Factor 1Fluorescent Antibody Technique 1Filgrastim 1Etoposide 1Cytarabine 1Cyclophosphamide 1Comparative Genomic Hybridization 1Carboplatin 1Amplified Fragment Length Polymorphism Analysis 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Central Nervous System Neoplasms × etoposide phosphate × Classical hematology × Clear all
NCT00074165 2023-07-06

Treating Patients With Recurrent PCNSL With Carboplatin/BBBD and Adding Rituxan To The Treatment Regimen

OHSU Knight Cancer Institute

Phase 2 Terminated
17 enrolled 7 charts
CNSClassical hematologyLymphoid

Lymphoma, Thrombocytopenia, Central Nervous System Neoplasms, Intraocular Lymphoma, Drug-Related Side Effects and Adverse Reactions

Data powered by HemOnc (CC BY 4.0) Colophon âš¡